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Background
Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) 
are associated with favorable survival, but the independent prognostic significance 
of tumor HPV status remains unknown.
Methods
We performed a retrospective analysis of the association between tumor HPV status 
and survival among patients with stage III or IV oropharyngeal squamous-cell car-
cinoma who were enrolled in a randomized trial comparing accelerated-fractionation 
radiotherapy (with acceleration by means of concomitant boost radiotherapy) with 
standard-fractionation radiotherapy, each combined with cisplatin therapy, in pa-
tients with squamous-cell carcinoma of the head and neck. Proportional-hazards 
models were used to compare the risk of death among patients with HPV-positive 
cancer and those with HPV-negative cancer.
Results
The median follow-up period was 4.8 years. The 3-year rate of overall survival was 
similar in the group receiving accelerated-fractionation radiotherapy and the group 
receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P = 0.18; hazard ratio 
for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval 
[CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total 
of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tu-
mors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% 
among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after 
adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment 
assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 
0.27 to 0.66). The risk of death significantly increased with each additional pack-
year of tobacco smoking. Using recursive-partitioning analysis, we classified our pa-
tients as having a low, intermediate, or high risk of death on the basis of four factors: 
HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage.
Conclusions
Tumor HPV status is a strong and independent prognostic factor for survival among 
patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)
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The majority of patients enrolled in therapeutic trials for squamous-cell carci-noma of the head and neck have oropha-
ryngeal squamous-cell carcinoma, which in a sub-
group of these patients is caused by infection with 
human papillomavirus (HPV).1 This subgroup is 
defined by the presence of high-risk types of HPV 
in tumor cells, predominantly HPV type 16 (HPV-
16). Expression of viral E6 and E7 oncoproteins 
that inactivate the tumor-suppressor proteins p53 
and the retinoblastoma protein (pRb), respective-
ly, is necessary for malignant behavior of these 
tumors.2
Several retrospective case series have shown 
that among patients with oropharyngeal squa-
mous-cell carcinoma, patients with HPV-positive 
tumors have a better prognosis than patients with 
HPV-negative tumors.3 Similar findings were 
reported in a prospective analysis of data from a 
clinical trial.4 Because of the small sample, how-
ever, other favorable prognostic factors associated 
with tumor HPV status (e.g., early tumor stage or 
young age) could not be ruled out as an explana-
tion for the observed difference in survival.
We sought to evaluate the effect of tumor HPV 
status on survival in patients with oropharyngeal 
squamous-cell carcinoma who were enrolled in a 
clinical trial of sufficient size to account for po-
tentially confounding factors, including smoking 
status. Our analysis was performed within a ran-
domized clinical trial conducted by the Radiation 
Therapy Oncology Group (RTOG; the RTOG 0129 
study). Meta-analyses of clinical trials for patients 
with locally advanced squamous-cell carcinoma of 
the head and neck have shown that both acceler-
ated-fractionation radiotherapy5 and concurrent 
cisplatin-based chemotherapy improved survival as 
compared with standard-fractionation radiother-
apy alone.6 The RTOG 0129 study addressed the 
question of whether accelerated-fractionation ra-
diotherapy is superior to standard-fractionation 
radiotherapy when each radiotherapy regimen is 
combined with concurrent cisplatin therapy. We 
report the results of this trial with an emphasis 
on the effect of tumor HPV status on survival 
among patients with oropharyngeal squamous-cell 
carcinoma.
Me thods
Study Protocol
The RTOG 0129 study was registered with the 
National Cancer Institute and approved by the in-
stitutional review boards at the participating cen-
ters. All patients provided written informed con-
sent. The authors attest to the fidelity of the article 
to the full protocol and statistical-analysis plan.
Eligibility criteria were the presence of un-
treated, pathologically confirmed, stage III or IV 
squamous-cell carcinoma of the oral cavity, oro-
pharynx, hypopharynx, or larynx without distant 
metastases (M0)7; Zubrod’s performance status 
score of 0 or 1 (asymptomatic or symptomatic but 
ambulatory, respectively)8; age of 18 years or 
older; and adequate bone marrow, hepatic, and 
renal function. Lifetime tobacco ex posure was de-
termined at enrollment with the use of a stan-
dardized, self-administered questionnaire.
Patients were stratified on the basis of the tu-
mor site (larynx vs. other), nodal stage (N0 vs. N1, 
N2a, or N2b vs. N2c or N3), and Zubrod’s perfor-
mance status score (0 vs. 1) and were randomly 
assigned to receive high-dose cisplatin concur-
rently with either accelerated-fractionation radio-
therapy (with the acceleration provided by means 
of concomitant boost radiotherapy) or standard-
fractionation radiotherapy. The accelerated-frac-
tionation radiotherapy consisted of the delivery 
of 72 Gy in 42 fractions over a 6-week period, with 
a concomitant boost of twice-daily irradiation for 
12 treatment days (as previously reported9), and 
standard-fractionation radiotherapy consisted of 
the delivery of 70 Gy in 35 fractions (i.e., 2 Gy 
per fraction) over a 7-week period. Intravenous 
cisplatin was administered at a dose of 100 mg per 
square meter of body-surface area on days 1 and 
22 in the accelerated-fractionation radiotherapy 
group and on days 1, 22, and 43 in the standard-
fractionation radiotherapy group.
Acute toxicity was evaluated weekly during 
the period of therapy according to the Common 
Terminology Criteria, version 2.0 (http://ctep 
.info.nih.gov/protocolDevelopment/electronic_ 
applications/docs/ctcv20_4-30-992.pdf). To as-
sess tumor status and late toxicity, according to 
RTOG criteria,10 physical examinations and im-
aging studies were performed every 3 months for 
the first 2 years, every 6 months during years 
3 through 5, and annually thereafter.
Laboratory Studies
The analysis of tumor HPV status was restricted 
to patients with oropharyngeal squamous-cell car-
cinoma because of the low prevalence of HPV 
among nonoropharyngeal squamous-cell carcino-
mas.1 This post hoc subgroup analysis was not 
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part of the study protocol. Formalin-fixed, paraf-
fin-embedded tumor specimens were evaluated for 
HPV-16 DNA with the use of the in situ hybridiza-
tion–catalyzed signal-amplification method for 
biotinylated probes (GenPoint, Dako).11 HPV-16–
negative tumors were further evaluated for 12 ad-
ditional oncogenic HPV types (18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, and 68) by means of a biotin-
ylated-probe cocktail (GenPoint HPV Probe Cock-
tail, Dako). An HPV-positive tumor was defined 
as a tumor for which there was specific staining 
of tumor-cell nuclei for HPV in either analysis.
Tumor p16 expression was evaluated by means 
of immunohistochemical analysis with a mouse 
monoclonal antibody (MTM Laboratories) visual-
ized with use of an autostainer (Ventana XT, 
Ventana) and a one-view secondary detection kit 
(Ventana).12 Positive p16 expression was defined 
as strong and diffuse nuclear and cytoplasmic 
staining in 70% or more of the tumor cells.12
Study End Points
The primary end point was overall survival, defined 
as the time from randomization to death. Second-
ary end points included progression-free survival, 
defined as the time from randomization to death 
or the first documented relapse, which was cate-
gorized as local–regional disease (tumor at the 
primary site or regional nodes) or distant metas-
tases. Death from the primary cancer without a 
documented site of recurrence or death from an 
unknown cause was considered death from local–
regional disease. Second primary tumors were 
evaluated separately. Progression-free survival and 
its components (local–regional disease and distant 
metastases) were reported instead of protocol-
specified secondary end points (e.g., disease-free 
survival) to facilitate comparison with published 
meta-analyses.13
Statistical Analysis
With a sample of 720 patients, the RTOG 0129 
study had 80% statistical power to detect a rela-
tive reduction of 25% in the rate of death in the 
accelerated-fractionation radiotherapy group as 
compared with the standard-fractionation radio-
therapy group, assuming a 2-year rate of overall 
survival of 45% in the standard-fractionation ra-
diotherapy group,14,15 with the use of a one-sided 
test at the 0.05 significance level.
Rates of overall survival and progression-free 
survival were estimated by means of the Kaplan–
Meier method and were compared between the 
two groups with the use of the log-rank test. The 
cumulative incidence method and Gray’s test were 
used to estimate and compare rates of local–
regional relapse, distant metastases, and second 
primary tumors.
Cox proportional-hazards models were used to 
estimate hazard ratios; multivariable models were 
developed by minimizing Akaike’s information 
criterion. Cox regression was performed with the 
use of data on tumor HPV status and smoking 
status, for patients for whom these data were 
available. Unadjusted and adjusted hazard ratios 
for HPV-positive and HPV-negative status were 
compared between the two groups to estimate 
the proportion of the difference in survival that 
was attributable to covariates. To investigate po-
tential bias in estimates due to missing data on 
HPV status, we repeated the analyses for the sub-
group of patients with oropharyngeal squamous-
cell carcinoma and for the entire RTOG study 
cohort (assuming the nonoropharyngeal squa-
mous-cell carcinoma tumors were HPV-negative), 
using values imputed with the Markov chain 
Monte Carlo algorithm with a noninformative 
prior distribution (SAS/STAT software, with SAS 
OnlineDoc 9.1.3; SAS Institute). Twenty data sets 
were created, and the resulting analyses were 
combined per Rubin’s formula.16 Recursive-par-
titioning analysis (for censored survival data) was 
performed with the use of S-Tree software (http://
peace.med.yale.edu/pub/stree) to identify the fac-
tors that were most influential for overall survival 
and to permit the classification of patients with 
oropharyngeal squamous-cell carcinoma as hav-
ing a low, intermediate, or high risk of death.17
R esult s
Characteristics of the Patients
From July 2002 through May 2005, a total of 743 
patients were enrolled in the RTOG 0129 study 
and randomly assigned to receive accelerated-frac-
tionation radiotherapy or standard-fractionation 
radiotherapy. Analyses were restricted to the 721 
patients who met the protocol study criteria (360 
patients in the accelerated-fractionation radiother-
apy group and the 361 patients in the standard-
fractionation radiotherapy group); of the remain-
ing 22 patients, 17 were found to be ineligible 
and 5 withdrew consent. The baseline charac-
teristics of the two groups are listed in Table 1.
The majority of enrolled patients (60.1% [433 
of 721]) had oropharyngeal squamous-cell carci-
The New England Journal of Medicine 
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noma, and HPV status was determined in 74.6% 
of these patients (323 of 433). Tumor specimens 
were not available for study in 94 patients, and 
tissue specimens from 16 patients did not con-
tain tumor tissue. No significant differences in 
baseline characteristics, overall survival, or pro-
gression-free survival were found between patients 
in whom HPV status was determined and those 
in whom it was not, arguing against significant 
selection bias (see the Supplementary Appendix, 
available with the full text of this article at NEJM 
.org). HPV DNA was detected in 63.8% of patients’ 
tumors (206 of the 323) by means of in situ hybrid-
ization, and 96.1% of the samples (198 of 206) 
were positive for HPV-16.
HPV-positive oropharyngeal cancer was more 
common among patients who had never smoked 
and those with a lower number of cumulative 
pack-years of tobacco smoking than among those 
with a history of heavier smoking and was also 
significantly associated with several favorable 
prognostic factors, including younger age, white 
race, better performance status, absence of ane-
mia, and smaller primary tumors (Table 1). The 
two treatment groups were balanced with regard 
to tumor HPV status.
Survival and Toxicity
There were no significant differences between the 
accelerated-fractionation radiotherapy group and 
the standard-fractionation radiotherapy group with 
regard to the rate of death within 30 days after 
the start of therapy (3.3% and 1.9%, respectively; 
P = 0.26) or the overall rates of grade 3 or 4 acute 
toxic events (80.0% and 83.7%, respectively; 
P = 0.21) and late toxic events (25.7% and 21.1%, 
respectively; P = 0.18). At the data cutoff point 
(August 2009), 418 patients were alive. After a 
median follow-up of 4.8 years (range, 0.3 to 6.5), 
there was no significant difference in the 3-year 
rate of overall survival between the accelerated-
fractionation radiotherapy group (70.3%; 95% con-
fidence interval [CI], 65.6 to 75.1) and the standard-
fractionation radiotherapy group (64.3%; 95% CI, 
59.3 to 69.2; P = 0.18). There was a nonsignificant 
reduction of 10% in the risk of death for the accel-
erated-fractionation radiotherapy group as com-
pared with the standard-fractionation radiother-
apy group (hazard ratio, 0.90; 95% CI, 0.72 to 
1.13), with a similar reduction in the subgroup of 
patients with HPV-positive cancer (11%; hazard ra-
tio, 0.89; 95% CI, 0.51 to 1.55) and in the subgroup 
with HPV-negative cancer (9%; hazard ratio, 0.91; 
95% CI, 0.69 to 1.19). The accelerated-fractionation 
radiotherapy group and the standard-fractionation 
radiotherapy group did not differ significantly with 
regard to progression-free survival or the pattern 
of relapse (see the Supplementary Appendix).
HPV Status and Survival
For analysis of the association of tumor HPV status 
with survival, we combined the data for all pa-
tients with oropharyngeal squamous-cell carcino-
ma, since the survival rates were similar in the two 
treatment groups. In a Kaplan–Meier analysis, pa-
tients with HPV-positive cancer had better overall 
survival and progression-free survival than pa-
tients with HPV-negative cancer (P<0.001 for both 
end points, by the log-rank test). The 3-year rates 
of overall survival were 82.4% (95% CI, 77.2 to 87.6) 
in the HPV-positive subgroup and 57.1% (95% CI, 
48.1 to 66.1) in the HPV-negative subgroup (Fig. 
1A), and the 3-year rates of progression-free sur-
vival were 73.7% (95% CI, 67.7 to 79.8) and 43.4% 
(95% CI, 34.4 to 52.4), respectively (Fig. 1B).
In the multivariable analysis, age, race, per-
formance status, tumor stage, nodal stage, and 
number of pack-years of tobacco smoking were 
also significant determinants of overall survival 
and progression-free survival (Table 2). By com-
paring the unadjusted hazard ratios for HPV-posi-
tive versus HPV-negative tumor status (hazard ratio 
for death, 0.38; 95% CI, 0.26 to 0.55; and hazard 
ratio for relapse or death, 0.40; 95% CI, 0.29 to 
0.57) (Fig. 1A and 1B) with the corresponding 
adjusted hazard ratios (provided below), we esti-
mated that these factors accounted for a relative 
difference of approximately 9% in the rates of 
overall survival and progression-free survival be-
tween patients with HPV-positive and those with 
HPV-negative oropharyngeal squamous-cell carci-
noma. Nonetheless, after this adjustment, patients 
with HPV-positive tumors had a 58% reduction in 
the risk of death as compared with patients with 
HPV-negative tumors (hazard ratio, 0.42; 95% CI, 
0.27 to 0.66) and a 51% reduction in the risk of 
relapse or death (hazard ratio, 0.49; 95% CI, 0.33 
to 0.74) (Table 2). After imputation for missing 
data, the results were similar (Table 2).
Tumors were evaluated for the expression of not 
only HPV but also a known biomarker of HPV-
oncoprotein function, the cyclin-dependent–kinase 
inhibitor p16, which is induced as a consequence 
of pRb inactivation by the HPV E7 oncoprotein18 
but is minimally detectable in HPV-negative tu-
mors because of epigenetic or genetic silencing.19 
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The presence of HPV DNA and the presence of 
p16 expression in tumors had very good agree-
ment (kappa = 0.80; 95% CI, 0.73 to 0.87). Using 
p16 expression as a stratification factor, we found 
differences in overall and progression-free survival 
that were consistent with those based on HPV 
status. In unadjusted analyses, the 3-year rate of 
overall survival was 83.6% (95% CI, 78.7 to 88.6) 
in the subgroup that was positive for p16 expres-
sion and 51.3% (95% CI, 41.5 to 61.0) in the sub-
group that was negative for p16 expression (haz-
ard ratio for death with positive p16 expression, 
0.29; 95% CI, 0.20 to 0.43) (Fig. 1C); the 3-year rate 
of progression-free survival was 74.4% (95% CI, 
68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9), 
respectively (hazard ratio for relapse or death with 
positive p16 expression, 0.33; 95% CI, 0.24 to 0.46) 
(Fig. 1D). After adjustment for other factors, the 
corresponding hazard ratio for death was 0.33 
(95% CI, 0.21 to 0.53), and the corresponding haz-
ard ratio for relapse or death was 0.42 (95% CI, 
0.28 to 0.64).
Table 1. Baseline Characteristics of the Study Patients and Their Tumors, According to Patient Group.*
Characteristic All Study Patients
Patients with Oropharyngeal Cancer  
and Known Tumor HPV Status
Standard- 
Fractionation 
Radiotherapy and 
Cisplatin (N = 361)
Accelerated-
Fractionation 
Radiotherapy and 
Cisplatin (N = 360)
HPV-Positive 
(N = 206)
HPV-Negative 
(N = 117) P Value†
Treatment assignment — no. (%) 0.86
Standard-fractionation radiotherapy  
and cisplatin
361 (100) 0 106 (51.5) 59 (50.4)
Accelerated-fractionation radiotherapy  
and cisplatin
0 360 (100) 100 (48.5) 58 (49.6)
Age — yr 0.02
Median 56.0 55.0 53.5 57.0
Range 34–82 26–82 31–78 37–82
Sex — no. (%) 0.10
Male 309 (85.6) 288 (80.0) 178 (86.4) 93 (79.5)
Female 52 (14.4) 72 (20.0) 28 (13.6) 24 (20.5)
Race — no. (%)‡ <0.001
White 290 (80.3) 299 (83.1) 190 (92.2) 88 (75.2)
Nonwhite 71 (19.7) 61 (16.9) 16 (7.8) 29 (24.8)
Zubrod’s performance status score — no. (%)§ 0.03
0 206 (57.1) 211 (58.6) 141 (68.4) 66 (56.4)
1 155 (42.9) 149 (41.4) 65 (31.6) 51 (43.6)
Anemia — no. (%)¶ 0.006
No 250 (69.3) 247 (68.6) 161 (78.2) 75 (64.1)
Yes 111 (30.7) 113 (31.4) 45 (21.8) 42 (35.9)
Primary site — no. (%)
Oral cavity 24 (6.6) 18 (5.0) 0 0
Oropharynx 216 (59.8) 217 (60.3) 206 (100) 117 (100)
Hypopharynx 31 (8.6) 27 (7.5) 0 0
Larynx 90 (24.9) 98 (27.2) 0 0
Tumor stage — no. (%) 0.006
T2 69 (19.1) 99 (27.5) 71 (34.5) 28 (23.9)
T3 169 (46.8) 159 (44.2) 84 (40.8) 43 (36.8)
T4 123 (34.1) 102 (28.3) 51 (24.8) 46 (39.3)
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Table 1. (Continued.)
Characteristic All Study Patients
Patients with Oropharyngeal Cancer  
and Known Tumor HPV Status
Standard- 
Fractionation 
Radiotherapy and 
Cisplatin (N = 361)
Accelerated-
Fractionation 
Radiotherapy and 
Cisplatin (N = 360)
HPV-Positive 
(N = 206)
HPV-Negative 
(N = 117) P Value†
Nodal stage — no. (%) 0.46
N0 67 (18.6) 69 (19.2) 15 (7.3) 9 (7.7)
N1 54 (15.0) 53 (14.7) 22 (10.7) 24 (20.5)
N2a 28 (7.8) 32 (8.9) 25 (12.1) 12 (10.3)
N2b 94 (26.0) 95 (26.4) 78 (37.9) 29 (24.8)
N2c 89 (24.7) 84 (23.3) 44 (21.4) 34 (29.1)
N3 29 (8.0) 27 (7.5) 22 (10.7) 9 (7.7)
AJCC stage — no. (%) 0.30
III 77 (21.3) 81 (22.5) 25 (12.1) 19 (16.2)
IV 284 (78.7) 279 (77.5) 181 (87.9) 98 (83.8)
Tobacco exposure — no. (%) <0.001
Never smoked 44 (12.2) 69 (19.2) 59 (28.6) 14 (12.0)
Former smoker 191 (52.9) 183 (50.8) 110 (53.4) 54 (46.2)
Current smoker 83 (23.0) 68 (18.9) 24 (11.7) 32 (27.4)
Unknown 43 (11.9) 40 (11.1) 13 (6.3) 17 (14.5)
Tobacco-smoking history — no. of pack-years‖ <0.001
Median 33 24 12.2 36.5
Range 0–137.5 0–152.0 0–152.0 0–96.0
HPV status of primary oropharyngeal tumor  
— no./total no. (%)
Positive 106/216 (49.1) 100/217 (46.1) 206/206 (100) 0
Negative 59/216 (27.3) 58/217 (26.7) 0 117/117 (100)
Unknown 51/216 (23.6) 59/217 (27.2) 0 0
p16 Expression in oropharyngeal primary  
tumor — no./total no. (%)
<0.001
Positive 114/216 (52.8) 101/217 (46.5) 192/206 (93.2) 22/117 (18.8)
Negative 48/216 (22.2) 53/217 (24.4) 7/206 (3.4) 94/117 (80.3)
Unknown 54/216 (25.0) 63/217 (29.0) 7/206 (3.4) 1/117 (0.9)
* AJCC denotes the American Joint Committee on Cancer, and HPV human papillomavirus.
† P values were calculated with the use of Pearson’s chi-square test for all comparisons, except age and pack-years, for which the Kolmogorov–
Smirnov test was used, and tumor stage and nodal stage, for which the Kruskal–Wallis test was used.
‡ Race was self-reported.
§ Zubrod’s performance status scores of 0 and 1 correspond to asymptomatic performance and symptomatic but ambulatory performance, 
respectively.
¶ Anemia was defined as a hemoglobin level of 13.5 g per deciliter or less for men and 12.5 g per deciliter or less for women.
‖ A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for 1 year. Data on pack-years were missing for 28 of the 
206 patients (13.6%) with HPV-positive tumors and 29 of the 117 patients (24.8%) with HPV-negative tumors.
Tobacco smoking was also independently as-
sociated with overall survival and progression-free 
survival both in the subgroup of patients with 
oropharyngeal squamous-cell carcinoma and in 
the entire study population (Table 2). The risks of 
death and cancer relapse or death significantly 
increased by 1% for each additional pack-year of 
tobacco smoking (Table 2), and the magnitude of 
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the tobacco effect was similar for patients with 
HPV-positive cancer (hazard ratio, 1.01; 95% CI, 
1.00 to 1.02) and those with HPV-negative cancer 
(hazard ratio, 1.01; 95% CI, 1.00 to 1.03).
In an analysis of patterns of treatment failure 
among patients with oropharyngeal squamous-cell 
carcinoma, the 3-year rate of local–regional dis-
ease, but not distant metastasis, was significantly 
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Figure 1. Kaplan–Meier Estimates of Survival among the Study Patients with Oropharyngeal Cancer, According to Tumor HPV  Status  
or p16-Expression Status.
Data on overall survival and progression-free survival are shown according to stratification on the basis of tumor HPV status (Panels A 
and B, respectively) or p16-expression status (Panels C and D, respectively). The Kaplan–Meier curves are shown in black, and the asso-
ciated 95% confidence intervals in gray. Patients with HPV-positive tumors had significantly better overall survival and progression-free 
survival than did patients with HPV-negative tumors (P<0.001 for both comparisons by the two-sided log-rank test). The 3-year rates of 
overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative 
subgroup (Panel A), and the 3-year rates of progression-free survival were 73.7% (95% CI, 67.7 to 79.8) and 43.4% (95% CI, 34.4 to 52.4), 
respectively (Panel B). The 3-year absolute benefit of HPV-positive status for overall survival was 25 percentage points (95% CI, 11 to 
40), and the absolute benefit for progression-free survival was 30 percentage points (95% CI, 15 to 45). The results were similar with 
stratification according to p16-expression status. The 3-year rates of overall survival were 83.6% (95% CI, 78.7 to 88.6) in the subgroup 
that was positive for p16 expression and 51.3% (95% CI, 41.5 to 61.0) in the subgroup that was negative for p16 expression (P<0.001) 
(Panel C), and the 3-year rates of progression-free survival were 74.4% (95% CI, 68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9), respec-
tively (P<0.001) (Panel D).
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lower for patients with HPV-positive tumors than 
for those with HPV-negative tumors (13.6% vs. 
35.1%, P<0.001) (Table 3). In addition, the cumu-
lative incidence of second primary tumors was 
significantly lower among patients with HPV-posi-
tive tumors, largely because of lower rates of 
smoking-related cancer (Table 3).
Recursive-partitioning analysis showed that the 
HPV status of the tumor was the major determi-
nant of overall survival, followed by the number 
of pack-years of tobacco smoking (≤10 vs. >10) 
and then nodal stage (N0 to N2a vs. N2b to N3), 
for HPV-positive tumors, or tumor stage (T2 or T3 
vs. T4), for HPV-negative tumors (Fig. 2A). This 
analysis classified patients with oropharyngeal 
squamous-cell carcinoma into three categories 
with respect to the risk of death: low risk, with 
a 3-year rate of overall survival of 93.0%; interme-
diate risk, with a 3-year rate of 70.8% (hazard ratio 
for the comparison with low risk, 3.54; 95% CI, 
1.91 to 6.57); and high risk, with a 3-year rate of 
46.2% (hazard ratio for the comparison with low 
risk, 7.16; 95% CI, 3.97 to 12.93) (Fig. 2B). Patients 
with HPV-positive tumors were considered to be 
Table 2. Hazard Ratios for Overall and Progression-free Survival, According to Patient Group.
Covariate Patients with Oropharyngeal Cancer
All Patients, with Data  
Imputed (N = 721)
Complete Data (N = 266) Data Imputed (N = 433)
hazard ratio 
(95% CI) P value
hazard ratio 
(95% CI) P value
hazard ratio 
(95% CI) P value
Overall survival
Treatment assignment (accelerated- vs. standard-
fractionation radiotherapy)
1.24 (0.81–1.89) 0.32 1.09 (0.78–1.52) 0.61 0.98 (0.78–1.23) 0.87
Age (>50 yr vs. ≤50 yr) 1.62 (0.96–2.74) 0.07 1.69 (1.12–2.56) 0.01 1.35 (1.02–1.80) 0.03
Race (nonwhite vs. white) 1.57 (0.89–2.75) 0.12 2.13 (1.39–3.25) <0.001 1.56 (1.18–2.05) 0.002
Tumor stage (T4 vs. T2–T3) 2.15 (1.40–3.29) <0.001 2.00 (1.43–2.80) <0.001 1.85 (1.46–2.34) <0.001
Nodal stage (N2b–N3 vs. N0–N2a) 1.99 (1.24–3.21) 0.005 1.91 (1.30–2.79) <0.001 1.68 (1.33–2.14) <0.001
Pack-years of smoking (per increase of 1 yr) 1.01 (1.00–1.02) 0.003 1.01 (1.01–1.02) <0.001 1.01 (1.00–1.01) 0.002
HPV status (positive vs. negative) 0.42 (0.27–0.66) <0.001 0.50 (0.33–0.76) 0.002 0.41 (0.29–0.57) <0.001
HPV status (negative vs. positive) 2.38 (1.51–3.74) <0.001 2.00 (1.31–3.06) 0.002 2.44 (1.75–3.41) <0.001
Progression-free survival
Treatment assignment (accelerated- vs. standard-
fractionation radiotherapy)
1.19 (0.81–1.73) 0.38 1.12 (0.83–1.50) 0.46 1.06 (0.86–1.31) 0.58
Age (>50 yr vs. ≤50 yr) 1.69 (1.05–2.72) 0.03 1.73 (1.20–2.50) 0.003 1.39 (1.08–1.80) 0.01
Race (nonwhite vs. white) 1.43 (0.85–2.39) 0.18 1.66 (1.13–2.44) 0.01 1.41 (1.09–1.82) 0.009
Zubrod’s performance status score (1 vs. 0) 1.42 (0.97–2.09) 0.07 1.44 (1.05–1.96) 0.02 1.51 (1.22–1.88) <0.001
Tumor stage (T4 vs. T2–T3) 1.48 (1.00–2.20) 0.05 1.32 (0.96–1.80) 0.08 1.43 (1.15–1.78) 0.001
Nodal stage (N2b–N3 vs. N0–N2a) 1.60 (1.06–2.42) 0.03 1.51 (1.09–2.10) 0.01 1.54 (1.24–1.91) <0.001
Pack-years of smoking (per increase of 1 yr) 1.01 (1.00–1.02) 0.002 1.01 (1.00–1.01) 0.002 1.01 (1.00–1.01) 0.002
HPV status (positive vs. negative) 0.49 (0.33–0.74) <0.001 0.53 (0.37–0.76) <0.001 0.48 (0.36–0.65) <0.001
HPV status (negative vs. positive) 2.02 (1.35–3.03) <0.001 1.88 (1.31–2.70) <0.001 2.06 (1.55–2.75) <0.001
* HPV denotes human papillomavirus. Estimates for each covariate have been adjusted for all other covariates listed. The data that were im-
puted (with the use of 20 imputations) were data on HPV status and number of pack-years. Missing HPV status was imputed for 110 pa-
tients with primary oropharyngeal cancer. Patients with a nonoropharyngeal primary site were assumed to have HPV-negative tumors. 
Missing number of pack-years was imputed for a total of 163 patients, 80 of whom had oropharyngeal cancer. Using the unadjusted hazard 
ratio for death among patients with HPV-negative (vs. HPV-positive) tumors of 2.62, we estimated that the covariates could account for 9% 
(100 × [1 – 2.38 ÷ 2.62]) of the different in survival between patients with HPV-positive tumors and those with HPV-negative tumors in the 
model with complete data and up to 25% (100 × [1–2.00 ÷ 2.62]) in the model with imputations. In a model with data from all patients, with 
HPV-positive oropharyngeal squamous-cell carcinoma as the reference group, HPV-negative oropharyngeal squamous-cell carcinoma and 
nonoropharyngeal squamous-cell carcinoma were associated with similar hazard ratios for death (2.29 and 2.55, respectively) and relapse or 
death (2.02 and 2.09, respectively).
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at low risk, with the exception of smokers with a 
high nodal stage (i.e., N2b to N3), who were con-
sidered to be at intermediate risk; patients with 
HPV-negative tumors were considered to be at high 
risk, with the exception of nonsmokers with tu-
mors of stage T2 or T3, who were considered to 
be at intermediate risk.
Discussion
This study provides strong evidence that tumor 
HPV status is an independent prognostic factor 
for overall survival and progression-free survival 
among patients with oropharyngeal squamous-cell 
carcinomas, which is consistent with the hypoth-
esis that HPV-positive and HPV-negative oropha-
ryngeal squamous-cell carcinomas are distinct and 
have different causes,20 risk-factor profiles,1 and 
survival outcomes. On the basis of our data, we 
believe that future clinical trials should be de-
signed specifically for patients with HPV-positive 
or HPV-negative squamous-cell carcinoma of the 
head and neck or patients who have been strati-
fied according to HPV status. Moreover, addition-
Table 3. Survival Estimates, Causes of Death, and Patterns of Treatment Failure in Patients with Oropharyngeal Cancer, 
According to Tumor HPV Status.*
Variable
HPV-Positive 
(N = 206)
HPV-Negative 
(N = 117) P Value†
Overall survival at 3 yr — % (95% CI) 82.4 (77.2–87.6) 57.1 (48.1–66.1) <0.001
Cause of death — no. of patients/total no. (%) 0.67
Primary cancer 25/50 (50.0) 29/58 (50.0)
Second primary tumor 4/50 (8.0) 8/58 (13.8)
Protocol treatment 1/50 (2.0) 0/58
Nonprotocol treatment 1/50 (2.0) 1/58 (1.7)
Cause unrelated to cancer or treatment 10/50 (20.0) 8/58 (13.8)
Unknown 9/50 (18.0) 12/58 (20.7)
Progression-free survival at 3 yr — % (95% CI) 73.7 (67.7–79.8) 43.4 (34.4–52.4) <0.001
Local–regional relapse at 3 yr — % (95% CI) 13.6 (8.9–18.3) 35.1 (26.4–43.8) <0.001
Distant metastasis at 3 yr — % (95% CI) 8.7 (4.9–12.6) 14.6 (8.1–21.1) 0.23
Type of first treatment failure — no. of patients/total no. (%) 0.55
Local–regional disease 26/66 (39.4) 33/72 (45.8)
Distant metastasis 21/66 (31.8) 17/72 (23.6)
Death, no documented progression 19/66 (28.8) 22/72 (30.6)
Second primary tumor at 3 yr — % (95% CI) 5.9 (2.6–9.1) 14.6 (8.1–21.0) 0.02
Site of second primary tumor — no. of patients/total no. (%) 0.91
Head and neck 5/19 (26.3) 5/21 (23.8)
Lung 8/19 (42.1) 9/21 (42.9)
Prostate 2/19 (10.5) 2/21 (9.5)
Colon 0/19 1/21 (4.8)
Rectum 0/19 1/21 (4.8)
Kidney 0/19 1/21 (4.8)
Breast 0/19 1/21 (4.8)
Skin 3/19 (15.8) 1/21 (4.8)
Unknown 1/19 (5.3) 0/21
* HPV denotes human papillomavirus.
† P values were calculated with the use of Gray’s test, except for overall and progression-free survival, for which the log-
rank test was used, and cause of death, type of first treatment failure, and site of second primary tumor, for which 
Pearson’s chi-square test was used. The P value for the cause of death was calculated with primary cancer, protocol 
treatment, and nonprotocol treatment combined. The P value for the site of a second primary tumor was calculated 
with head and neck cancer and lung cancer (both of which are considered to be related to smoking) combined.
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al information could be gleaned from completed 
clinical trials, by means of reanalysis, to deter-
mine whether imbalances in tumor HPV status 
between treatment groups affected the outcomes 
and thus the therapeutic implications.
Our analysis of the association of HPV status 
with survival was performed in a clinical trial of 
locally advanced squamous-cell carcinoma of the 
head and neck that did not show a significant dif-
ference in overall survival between a concomitant-
boost accelerated-fractionation regimen of radio-
therapy and a standard-fractionation regimen, 
combined with concurrent, high-dose cisplatin. 
Therefore, either regimen could serve as the com-
parison for a new therapy being investigated.
We observed strong agreement between tumor 
HPV status, as determined by in situ hybridization, 
and expression of p16, an established biomarker 
for the function of the HPV E7 oncoprotein. Our 
HPV-16 in situ hybridization assay has sensitivity 
for single viral copies, and a positive result is 
strongly correlated with expression of the HPV 
E6 and E7 oncogenes — the standard for defin-
ing a tumor as being associated with HPV.21,22 
A limitation of our method is the unknown sen-
sitivity of the probe cocktail for non–HPV-16 types, 
which account for an estimated 5 to 10% of HPV-
positive oropharyngeal squamous-cell carcino-
mas.23 Thus, the misclassification of HPV-positive 
tumors as HPV-negative tumors probably explains 
the slightly larger reduction in the risk of death 
when the analysis was based on status with respect 
to p16 expression rather than HPV presence. 
A strength of the p16-expression assay is that it 
is not specific for HPV type, unlike the in situ 
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Figure 2. Classification of the Study Patients into Risk-
of-Death Categories and Kaplan–Meier Estimates of 
Overall Survival According to Those Categories.
Recursive-partitioning analysis was used to identify 
prognostic factors with the most influential predictive 
significance in a proportional-hazards model of overall 
survival and to classify patients into categories of low, 
intermediate, or high risk of death. The prognostic fac-
tors in the analysis were age, tumor stage, nodal stage, 
race, smoking status, HPV status, anemia status, per-
formance status, treatment assignment, and sex. Panel 
A shows the resulting classifications. Panel B shows 
data for overall survival in the classified patients. The 
Kaplan–Meier curves are shown in black, and the asso-
ciated 95% confidence intervals in gray. The 3-year 
rates of overall survival were 93.0% (95% CI, 88.3 to 
97.7) in the low-risk group, 70.8% (95% CI, 60.7 to 
80.8) in the intermediate-risk group, and 46.2% (95% 
CI, 34.7 to 57.7) in the high-risk group. Hazard ratios 
for death among the 266 patients for whom the risk 
classification could be made on the basis of the re-
corded data and among all 433 patients with oropha-
ryngeal cancer (after missing data on HPV status and 
number of pack-years were estimated with the use of 
statistical imputation) were as follows: 3.54 (95% CI, 
1.91 to 6.57) and 2.67 (95% CI, 1.54 to 4.62), respec-
tively, in the intermediate-risk group versus the low-
risk group; and 7.16 (95% CI, 3.97 to 12.93) and 5.23 
(95% CI, 3.14 to 8.73), respectively, in the high-risk 
group versus the low-risk group.
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hybridization assays; therefore, p16-expression sta-
tus is a very good surrogate for tumor HPV status.
The superior prognosis for HPV-positive oro-
pharyngeal squamous-cell carcinoma, as com-
pared with that for the HPV-negative cancer, ap-
pears to have multifactorial underpinnings. Known 
favorable prognostic factors associated with the 
HPV-positive subgroup account for approximately 
10% of the detected difference in outcome. The 
higher survival rate among patients with HPV-
positive cancer is due in part to greater local–
regional control, reflecting higher intrinsic sensi-
tivity to radiation or better radiosensitization with 
the use of cisplatin. Although rates of response 
to induction chemotherapy are higher among pa-
tients with HPV-positive tumors than among those 
with HPV-negative tumors,4 single-agent cisplatin 
therapy did not appear to differentially affect the 
elimination of occult distant metastases. Second 
primary tumors, which are largely related to smok-
ing, were less frequent among patients with HPV-
positive tumors, a finding that is consistent with 
the lower exposure to tobacco in this subgroup. 
However, the rates of death from second primary 
tumors were similar in the HPV-positive and HPV-
negative subgroups and therefore do not account 
for the overall differences in survival rates.
Our data clearly indicate that HPV status and 
status with respect to tobacco smoking are major 
independent prognostic factors for patients with 
oropharyngeal squamous-cell carcinoma, proba-
bly because they determine the molecular profile 
of the cancer and thus the response to therapy. 
Although HPV-positive oro pharyngeal squamous-
cell carcinoma is genetically distinct from the 
HPV-negative cancer with respect to patterns of 
loss of heterozygosity,24 chromosomal abnormali-
ties,25,26 and gene-expression profiles27 and is in-
versely correlated with biomarkers for a poor 
prognosis in squamous-cell carcinoma of the head 
and neck (e.g., p53 mutations28 or expression of 
epidermal growth factor receptor29), no specific 
mechanism has been shown to explain the higher 
rates of response to radiation therapy and chemo-
therapy among patients with HPV-positive cancer.4 
Epidemiologic data indicate that tobacco smok-
ing is not a strong cofactor for the development 
of HPV-positive oropharyngeal squamous-cell car-
cinoma.1 Nevertheless, our data reveal that the 
biologic behavior of an HPV-positive tumor may 
be altered by tobacco use. Genetic alterations in-
duced by tobacco-associated carcinogens may ren-
der HPV-positive tumors less responsive to ther-
apy. The likelihood of such genetic alterations 
appears to increase as the number of pack-years 
of tobacco smoking increases (Table 2). The cut-
off point of 10 pack-years, which was the best 
predictor of survival in our recursive-partitioning 
analysis, may be more useful than a continuum 
for the design of future risk-based clinical trials 
but will require further validation.
The extent to which the superior survival for a 
patient with HPV-positive oropharyngeal squamous-
cell carcinoma depends on the administered ther-
apy is unclear. Published data indicate that tumor 
HPV status is a strong and consistent determinant 
of superior survival, regardless of treatment strat-
egy (e.g., surgery,30 radiation therapy,31,32 concur-
rent chemoradiation therapy [in this study], or 
induction chemotherapy plus concurrent chemo-
radiation therapy4,33), with 5-year survival rates 
among patients with HPV-positive tumors of ap-
proximately 75 to 80%, versus 45 to 50% among 
patients with HPV-negative tumors.
Though no direct evidence from formal clini-
cal trials exists to guide treatment decisions for 
the individual patient on the basis of tumor HPV 
status, this study provides a direction for future 
clinical research. A combination of tumor HPV 
status, pack-years of tobacco smoking, and cancer 
stage may be used to classify patients as having 
a low, intermediate, or high risk of death. Wheth-
er patients with HPV-positive tumors who are 
considered to be in the low-risk category can be 
spared the long-term complications of intensive, 
multimodal therapy without compromising their 
survival is now a highly relevant clinical question. 
In contrast, such a strategy would be inappropri-
ate for the 36% of patients with HPV-positive tu-
mors who are in the intermediate-risk group, for 
whom the 3-year rate of overall survival (71%, with 
an even lower rate of progression-free survival) is 
unacceptable. Unfortunately, patients in the high-
risk group have an extremely poor prognosis and 
thus should be offered enrollment in trials test-
ing more intensive investigational therapies. Should 
our risk model be validated in other cohorts, it 
will be important to incorporate tumor HPV 
status and tobacco exposure as nonanatomical 
determinants of risk classification and therapy 
selection for patients with oropharyngeal squa-
mous-cell carcinoma.
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